Cargando…
Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans
Atrial fibrillation (AF) is the most persistent arrhythmia today, with its prevalence increasing exponentially with the rising age of the population. Particularly at elevated heart rates, a functional abnormality known as cardiac alternans can occur prior to the onset of lethal arrhythmias. Cardiac...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959422/ https://www.ncbi.nlm.nih.gov/pubmed/36826532 http://dx.doi.org/10.3390/jcdd10020036 |
_version_ | 1784895272581595136 |
---|---|
author | Muthavarapu, Neha Mohan, Anmol Manga, Sharanya Sharma, Palak Bhanushali, Aditi Kishor Yadav, Ashima Damani, Devanshi Narendra Jais, Pierre Walton, Richard D. Arunachalam, Shivaram P. Kulkarni, Kanchan |
author_facet | Muthavarapu, Neha Mohan, Anmol Manga, Sharanya Sharma, Palak Bhanushali, Aditi Kishor Yadav, Ashima Damani, Devanshi Narendra Jais, Pierre Walton, Richard D. Arunachalam, Shivaram P. Kulkarni, Kanchan |
author_sort | Muthavarapu, Neha |
collection | PubMed |
description | Atrial fibrillation (AF) is the most persistent arrhythmia today, with its prevalence increasing exponentially with the rising age of the population. Particularly at elevated heart rates, a functional abnormality known as cardiac alternans can occur prior to the onset of lethal arrhythmias. Cardiac alternans are a beat-to-beat oscillation of electrical activity and the force of cardiac muscle contraction. Extensive evidence has demonstrated that microvolt T-wave alternans can predict ventricular fibrillation vulnerability and the risk of sudden cardiac death. The majority of our knowledge of the mechanisms of alternans stems from studies of ventricular electrophysiology, although recent studies offer promising evidence of the potential of atrial alternans in predicting the risk of AF. Exciting preclinical and clinical studies have demonstrated a link between atrial alternans and the onset of atrial tachyarrhythmias. Here, we provide a comprehensive review of the clinical utility of atrial alternans in identifying the risk and guiding treatment of AF. |
format | Online Article Text |
id | pubmed-9959422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99594222023-02-26 Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans Muthavarapu, Neha Mohan, Anmol Manga, Sharanya Sharma, Palak Bhanushali, Aditi Kishor Yadav, Ashima Damani, Devanshi Narendra Jais, Pierre Walton, Richard D. Arunachalam, Shivaram P. Kulkarni, Kanchan J Cardiovasc Dev Dis Review Atrial fibrillation (AF) is the most persistent arrhythmia today, with its prevalence increasing exponentially with the rising age of the population. Particularly at elevated heart rates, a functional abnormality known as cardiac alternans can occur prior to the onset of lethal arrhythmias. Cardiac alternans are a beat-to-beat oscillation of electrical activity and the force of cardiac muscle contraction. Extensive evidence has demonstrated that microvolt T-wave alternans can predict ventricular fibrillation vulnerability and the risk of sudden cardiac death. The majority of our knowledge of the mechanisms of alternans stems from studies of ventricular electrophysiology, although recent studies offer promising evidence of the potential of atrial alternans in predicting the risk of AF. Exciting preclinical and clinical studies have demonstrated a link between atrial alternans and the onset of atrial tachyarrhythmias. Here, we provide a comprehensive review of the clinical utility of atrial alternans in identifying the risk and guiding treatment of AF. MDPI 2023-01-20 /pmc/articles/PMC9959422/ /pubmed/36826532 http://dx.doi.org/10.3390/jcdd10020036 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Muthavarapu, Neha Mohan, Anmol Manga, Sharanya Sharma, Palak Bhanushali, Aditi Kishor Yadav, Ashima Damani, Devanshi Narendra Jais, Pierre Walton, Richard D. Arunachalam, Shivaram P. Kulkarni, Kanchan Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans |
title | Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans |
title_full | Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans |
title_fullStr | Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans |
title_full_unstemmed | Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans |
title_short | Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans |
title_sort | targeted atrial fibrillation therapy and risk stratification using atrial alternans |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959422/ https://www.ncbi.nlm.nih.gov/pubmed/36826532 http://dx.doi.org/10.3390/jcdd10020036 |
work_keys_str_mv | AT muthavarapuneha targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT mohananmol targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT mangasharanya targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT sharmapalak targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT bhanushaliaditikishor targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT yadavashima targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT damanidevanshinarendra targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT jaispierre targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT waltonrichardd targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT arunachalamshivaramp targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans AT kulkarnikanchan targetedatrialfibrillationtherapyandriskstratificationusingatrialalternans |